BIM
SCLN

BlackRock Investment Management’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

BlackRock Investment Management’s Portfolio SCLN Stock Details SCLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$2.8M Buy
259,023
+40,344
+18% +$403K ﹤0.01% 1989
2016
Q3 		$2.24M Sell
218,679
-374
-0.2% -$4.07K ﹤0.01% 2061
2016
Q2 		$2.86M Buy
219,053
+42,382
+24% +$555K ﹤0.01% 1848
2016
Q1 		$1.94M Buy
176,671
+2,896
+2% +$25.8K ﹤0.01% 2032
2015
Q4 		$1.6M Sell
173,775
-18
-0% -$151 ﹤0.01% 2245
2015
Q3 		$1.21M Sell
173,793
-4,642
-3% -$39.8K ﹤0.01% 2463
2015
Q2 		$1.75M Buy
178,435
+19,777
+12% +$180K ﹤0.01% 2353
2015
Q1 		$1.41M Buy
158,658
+1,682
+1% +$13.4K ﹤0.01% 2285
2014
Q4 		$1.38M Sell
156,976
-825
-0.5% -$6.68K ﹤0.01% 2326
2014
Q3 		$1.09M Sell
157,801
-192
-0.1% -$1.15K ﹤0.01% 2471
2014
Q2 		$831K Sell
157,993
-2,904
-2% -$14.1K ﹤0.01% 2738
2014
Q1 		$732K Buy
160,897
+2,174
+1% +$10.5K ﹤0.01% 2739
2013
Q4 		$800K Sell
158,723
-3,381
-2% -$16.3K ﹤0.01% 2663
2013
Q3 		$822K Buy
162,104
+4,476
+3% +$24.9K ﹤0.01% 2586
2013
Q2 		$782K Buy
+157,628
New +$750K ﹤0.01% 2541

Other funds holding SCLN

BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return

BlackRock Investment Management's SCLN Position: Q4 2016 in Review

BlackRock Investment Management increased its Sciclone Pharmaceuticals Inc (SCLN) stake by 18% in Q4 2016, buying an estimated $403K and bringing the position to 259,023 shares worth $2.8M. The position accounts for ﹤0.01% of the portfolio, ranked #1989.

BlackRock Investment Management first reported a position in SCLN in Q2 2013 and has held it in 15 quarters since. The position peaked at $2.86M in Q2 2016. 153 funds tracked by Wall St. Rank hold SCLN as of Q4 2016.

  • BlackRock Investment Management held 259,023 shares of Sciclone Pharmaceuticals Inc worth $2.8M as of Q4 2016.
  • BlackRock Investment Management bought 40,344 Sciclone Pharmaceuticals Inc shares in Q4 2016, an estimated $403K.
  • Sciclone Pharmaceuticals Inc made up ﹤0.01% of BlackRock Investment Management's portfolio in Q4 2016, its #1989 holding.
  • BlackRock Investment Management first reported a position in Sciclone Pharmaceuticals Inc in Q2 2013 and has held it in 15 quarters since.
  • BlackRock Investment Management's Sciclone Pharmaceuticals Inc position peaked at $2.86M in Q2 2016.
  • 153 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q4 2016.

Based on BlackRock Investment Management's 13F filing for Q4 2016, filed 10 Feb 2017.